Paper Details

  1. Home
  2. Paper Details

Comparison of Acute Followed by Maintenance ECT vs Clozapine on Psychopathology and Regional Cerebral Blood Flow in Treatment-Resistant Schizophrenia: A Randomized Controlled Trial.

Author: AgrawalKanhaiyalal, BiswasTathagata, MaitiRituparna, MishraBiswa Ranjan, MohapatraDebadatta, NathSantanu

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This open-label trial compared the efficacy of maintenance electroconvulsive therapy (M-ECT) with clozapine for treatment-resistant schizophrenia (TRS). 60 TRS patients were randomly assigned to either M-ECT or clozapine. M-ECT demonstrated greater efficacy in reducing positive and negative symptoms, improving global functionality, and increasing regional cerebral perfusion.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND HYPOTHESIS: In treatment-resistant schizophrenia (TRS), Clozapine is only approved treatment with undesirable side-effects, warranting better alternatives. Our hypothesis is acute followed by maintenance Electroconvulsive Therapy (M-ECT) will be comparable in efficacy and safety to Cl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212098/

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Treatment-Resistant Schizophrenia

Treatment-resistant schizophrenia (TRS) is a challenging condition, and conventional treatments often fall short. This study investigates the effectiveness and safety of acute followed by maintenance electroconvulsive therapy (M-ECT) compared to clozapine, the only FDA-approved treatment for TRS. The researchers conducted a randomized controlled trial to evaluate the relative efficacy of these two treatment approaches.

A Comparative Journey: M-ECT vs. Clozapine

The researchers found that M-ECT was significantly more effective than clozapine in reducing positive and negative symptoms, general psychopathology, and improving global functionality in patients with TRS. Furthermore, M-ECT showed a positive correlation between improvement in symptoms and increased perfusion in the prefrontal and temporal cortices.

Navigating the Desert: Exploring New Pathways

The study provides compelling evidence for the effectiveness of M-ECT as a treatment option for TRS. The researchers highlight the potential of M-ECT as a safe and effective alternative to clozapine, offering a new oasis in the desert of treatment-resistant schizophrenia.

Dr. Camel's Conclusion

This study offers a promising new avenue for treating patients with treatment-resistant schizophrenia. The researchers found that acute followed by maintenance electroconvulsive therapy (M-ECT) was more effective and safe than clozapine in reducing symptoms and improving functionality. This research represents a significant step forward in the treatment of TRS, providing a potential oasis in the desert of this challenging condition.
Date :
  1. Date Completed 2022-06-23
  2. Date Revised 2023-05-13
Further Info :

Pubmed ID

35556138

DOI: Digital Object Identifier

PMC9212098

Related Literature

Article Analysis
・Effective treatment of schizophrenia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.